第716号委员会意见:妇产科医生在平均风险女性上皮性卵巢癌早期检测中的作用
卵巢癌是第二常见的女性生殖系统癌症,死亡人数超过宫颈癌和子宫癌之和。目前尚无降低卵巢癌死亡率的早期检测策略。详细采集乳腺癌、妇科癌和结肠癌的个人史和家族史有助于按平均风险或高风险对女性分类;有卵巢癌、乳腺癌或结肠癌强家族史者可能存在遗传性乳腺癌卵巢癌综合征(BRCA突变)或遗传性非息肉病性结直肠癌(Lynch综合征),应转诊进行正式遗传咨询。对平均风险女性,经阴道超声和肿瘤标志物(如癌抗原125)单独或联合用于早期检测尚未被证明可降低死亡率,且假阳性结果导致的侵入性诊断检查(如手术)存在伤害。
要点
- 卵巢癌死亡人数超过宫颈癌和子宫癌之和,目前无降低死亡率的早期检测策略。
- 详细采集乳腺、妇科和结肠癌个人史和家族史,按平均风险或高风险分类。
- 有强家族史者应转诊正式遗传咨询,评估包括卵巢癌在内的癌症风险。
核心结论
- 目前尚无降低卵巢癌死亡率的早期检测策略;详细采集个人史和家族史有助于风险分类,有强家族史者应转诊遗传咨询。
- 对平均风险女性,经阴道超声和肿瘤标志物单独或联合用于早期检测尚未被证明降低死亡率,且假阳性导致的侵入性诊断检查存在伤害。
研究设计与样本
- 美国妇产科医师学会(Obstet Gynecol)发布的委员会意见。
主要发现
- 卵巢癌是第二常见的女性生殖系统癌症,死于卵巢癌的女性多于宫颈癌和子宫癌合计。
- 目前没有降低卵巢癌死亡率的早期检测策略。
- 有卵巢癌、乳腺癌或结肠癌强家族史的女性可能存在遗传性乳腺癌卵巢癌综合征(BRCA突变)或遗传性非息肉病性结直肠癌(Lynch综合征),卵巢癌风险增加。
- 对平均风险女性,经阴道超声和肿瘤标志物(如癌抗原125)单独或联合用于早期检测尚未被证明降低死亡率,假阳性结果导致的侵入性诊断检查(如手术)存在伤害。
临床怎么用
- 详细采集乳腺癌、妇科癌和结肠癌的个人史和家族史,按平均风险或高风险对女性分类。
- 有卵巢癌、乳腺癌或结肠癌强家族史的女性应转诊进行正式遗传咨询,以更好地评估包括卵巢癌风险在内的癌症风险。
- 如合适,可向这些女性提供额外的卵巢癌早期检测。
- 当存在潜在相关的卵巢癌体征和症状时,患者和其妇产科医生应保持适当警惕。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Ovarian cancer is the second most common type of female reproductive cancer, and more women die from ovarian cancer than from cervical cancer and uterine cancer combined. Currently, there is no strategy for early detection of ovarian cancer that reduces ovarian cancer mortality. Taking a detailed personal and family history for breast, gynecologic, and colon cancer facilitates categorizing women based on their risk (average risk or high risk) of developing epithelial ovarian cancer. Women with a strong family history of ovarian, breast, or colon cancer may have hereditary breast and ovarian cancer syndrome (BRCA mutation) or hereditary nonpolyposis colorectal cancer (Lynch syndrome), and these women are at increased risk of developing ovarian cancer. Women with these conditions should be referred for formal genetic counseling to better assess their cancer risk, including their risk of ovarian cancer. If appropriate, these women may be offered additional testing for early detection of ovarian cancer. The use of transvaginal ultrasonography and tumor markers (such as cancer antigen 125), alone or in combination, for the early detection of ovarian cancer in average-risk women have not been proved to reduce mortality, and harms exist from invasive diagnostic testing (eg, surgery) resulting from false-positive test results. The patient and her obstetrician-gynecologist should maintain an appropriate level of suspicion when potentially relevant signs and symptoms of ovarian cancer are present.
引用
- Committee Opinion No. 716: The Role of the Obstetrician-Gynecologist in the Early Detection of Epithelial Ovarian Cancer in Women at Average Risk. Obstet Gynecol. 2017. PMID: 28832487. doi:10.1097/AOG.0000000000002299
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。